All News

Rezpegaldesleukin is designed to balance the body’s immune system response through activation of regulatory T-cells.

Emerging data indicate that COVID-19 is also characterized by inflammation present in the heart and other organs

If approved, brensocatib will be the first and only approved treatment for bronchiectasis and the first within a new class of medicines, called dipeptidyl peptidase 1 inhibitors.

Pharmacists can recommend vitamin D supplements and vitamin D-rich foods to support healthy pregnancy outcomes.

The decision to end HYPERION (NCT04811092) comes after positive results from an interim analysis of the ZENITH trial (NCT04896008).

Richard Lewis discusses the critical role pharmacists and health care providers play in ensuring safe administration of IVIG for patients with CIDP.

Thalassemia, a chronic blood condition that reduces hemoglobin levels, requires a hands-on approach from pharmacists in patient monitoring and diagnosis.

Circulating lactate is increased in patients with myelofibrosis and corresponds with the remodeling of lactate export channel monocarboxylate transporter 4, suggesting a link with fibrosis establishment.

Vietnam war trauma continues to affect veterans’ health 50 years later.

The authors are optimistic that this method can be replicated to identify other allergens that manifest into eosinophilic esophagitis (EoE).

If approved, HLX11 could offer a more cost-effective alternative to pertuzumab for the treatment of human epidermal growth factor receptor 2-positive breast cancer.

BR55, an injection of perfluorobutane/nitrogen lipopeptide-coated microbubbles, could aid in the detection of angiogenesis and allow for earlier diagnosis in patients with Crohn disease.

The speed and scale of what’s coming with AI can only be imagined now, but without a doubt, our lives will change.

In the phase 3 CONNEX clinical trial program, iclepertin did not meet its primary and secondary end points.

The indication is for patients with endometrial cancer who may benefit from treatment with ACR-368 (Acrivon Therapeutics).

Pharmacists should educate patients on abelacimab's potential therapeutic impact on atrial fibrillation patients at risk of stroke.

J Ryan Shaw, PharmD, BCPS, BCOP, CPP, discusses the value of the ASTCT and CIBMTR Tandem Meeting 2025 as a platform for multidisciplinary collaboration, cutting-edge education, and advancing pharmacy practice in transplant and cellular therapy.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, discusses the logistical challenges and interprofessional strategies essential for delivering cellular therapies in outpatient settings, emphasizing the pharmacist's role in improving patient outcomes and addressing health disparities.

The therapeutic vaccine could provide patients with a non-surgical alternative to traditional treatment approaches.

Proper nutrition and awareness of potential side effects from GLP-1 medications are essential for patients undergoing treatment.

Molly Schiffer, PharmD, BCOP, discusses the logistical and operational challenges of delivering outpatient CAR T-cell therapy, emphasizing the benefits of outpatient treatment, including reduced costs, improved access to therapy, and better quality of life for patients.

These findings can lay the foundation for the development of machine learning models in chronic kidney disease (CKD) and kidney failure.

Compared with other treatments for myasthenia gravis, nipocalimab demonstrated more significant improvements in disability scores, with tolerable safety.

Africa's unparalleled genetic diversity presents both a challenge and an opportunity to advance precision medicine, with a focus on leveraging pharmacogenetics to improve drug efficacy and reduce adverse reactions.

Catriona Jamieson, MD, PhD, discusses the role of stress-activated base editors like ADAR1p150 and APOBEC enzymes in cancer progression and highlights innovative approaches to halt these processes and improve therapeutic outcomes.